Introduction
Angiogenesis, the process of new vessel development, plays an essential role in embryogenesis, but postnatal angiogenesis is limited to sites of abnormal vascular
surface. An activated vascular endothelium can be induced by tissue injury or wound healing, by hormonal cycling such as in pregnancy and ovulation, or by tumor-induced vessel growth. In all of these circumstances, platelets act as the initial responder to vascular change, and provide a flexible delivery system for angiogenesis related molecules [1] [2] [3] [4] . The process of postnatal angiogenesis is regulated by a continuous interplay of stimulators and inhibitors of angiogenesis, and their imbalance contributes to numerous inflammatory, malignant, ischemic, and immune disorders 5 . There is a revived interest in the overlap between angiogenesis and platelets 6 because a number of clinical trials have now shown that anticoagulation can improve cancer survival 7, 8 beyond the benefit derived from the treatment of deep vein thrombosis alone.
It is known that platelets stimulate endothelial cells in culture and can promote the assembly of capillary-like structures in vitro 9, 10 . Platelets may modulate angiogenesis by releasing promoters such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), and matrix metalloproteinases (MMPs) 1, 6, [11] [12] [13] [14] [15] [16] [17] [18] . The repertoire of angiogenesis inhibitors contained within platelets includes endostatin, platelet factor-4, thrombospondin-1, alpha-2-macroglobulin, plasminogen activator inhibitor-1, and angiostatin 19, 20 . Although platelets contain three types of secretory granules (α-granules, dense granules, and lysosomes), most angiogenic regulatory proteins have been localized to 〈 -granules. α-granules are 200-500 nm in size, and contain proteins that enhance the For personal use only. on October 31, 2017 . by guest www.bloodjournal.org From adhesive process, promote cell-cell interactions, and stimulate vascular repair. By adhering to the endothelium of injured organs and tissues, and then secreting the contents of their α-granules, platelets may be capable of depositing high concentrations of angiogenesis regulatory proteins in a localized manner.
A body of experimental data and clinical investigations suggests that platelets are major regulators of angiogenesis 21 . However, because platelets contain both pro-and antiangiogenic regulatory proteins and because it has been assumed that the contents of α-granules are homogeneous, it has been unclear how platelets could either stimulate or inhibit angiogenesis. We provide new details about the organization of angiogenesis regulatory proteins in the α-granules of platelets and address the mechanism of how the selective release of these granules leads to the regulation of angiogenesis. Here we report the novel finding that angiogenic and antiangiogenic proteins are segregated into different sets of α-granules in platelets. We provide a mechanism for the differential release of these α-granules, and show that these distinct populations of α-granules may be regulated by differential G-protein-mediated signaling pathways.
Materials and methods
Approval was obtained from the Partners Human Research Committee institutional review board, Boston, MA, for these studies. Informed consent was provided according to the Declaration of Helsinki.
Preparation of Resting Platelets
Human blood from healthy volunteers, drawn into 0.1 volume of Aster-Jandl anticoagulant, was centrifuged at 110 g for 10 min. All volunteers had not ingested
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From aspirin or other nonsteroidal anti-inflammatory drugs for at least 10 days prior to blood collection. The platelet-rich plasma was gel-filtered through a Sepharose 2B column equilibrated with a solution containing 145 mM NaCl, 10 mM Hepes, 10 mM glucose, 0.5 mM Na 2 HPO 4 , 5 mM KCl, 2 mM MgCl 2 , and 0.3% BSA, pH 7.4. The number of platelets was counted by fluorescence activated cell sorting and adjusted to 2 X 10 8 /ml.
The isolated platelet suspension was incubated at 37 o C for up to 1 hr. The resting state of the platelets was routinely confirmed by PAC1 antibody and anti-tubulin immunofluorescence staining.
Activation of platelets
Release of α-granules was examined in vitro in response to 10 µm AYPGK-NH2, a selective PAR4-activating peptide, or 8 µm TFLLR-NH2, a PAR1-activating peptide.
Peptides were prepared by solid-phase synthesis at the Peptide Synthesis Facility of Synbiocsi (Livermore, CA). Isolated platelets were exposed to PAR activating peptide or vehicle for 10 minutes, fixed with 4% formaldehyde for 20 minutes, attached to polylysine-coated coverslips, and then processed for immunofluorescence microscopy.
Megakaryocyte Cultures
Livers were recovered from mouse fetuses and single cell suspensions were generated using methods described previously 22 . Between the fourth and sixth day of megakaryocyte culture, cells were placed on a 1.5-3% albumin step gradient and sedimented 23 to obtain enriched populations of megakaryocytes.
Immunofluorescence Microscopy
Rabbit anti-VEGF antibody (Ab-1) and mouse anti-VEGF (Ab-7) were obtained 
Immunogold-electron microscopy
For preparation of cryosections, isolated human platelets were fixed with 4% paraformaldehyde in 0.1M Na Phosphate buffer, pH 7.4. After 2 hours of fixation at room temperature the cell pellets were washed with PBS containing 0.2M glycine to quench free aldehyde groups from the fixative. Prior to freezing in liquid nitrogen cell pellets were infiltrated with 2.3M sucrose in PBS for 15 minutes. Frozen samples were sectioned at -120° C, the sections were transferred to formvar-carbon coated copper grids and floated on PBS until the immunogold labeling was carried out. The gold labeling was carried out at room temperature on a piece of parafilm. All antibodies and protein A gold were diluted with 1% BSA. The diluted antibody solution was centrifuged for 1 minute at 14,000 rpm prior to labeling to avoid possible aggregates. All antibodies were used at a concentration of 1 µg/ml. Grids were floated on drops of 1% BSA for 10 minutes to block for nonspecific labeling, transferred to 5µl drops of primary antibody and incubated for 30 minutes. The grids were then washed in 4 drops of PBS for a total of 15 minutes, transferred to 5µl drops of Protein-A gold for 20 minutes, washed in 4 drops of PBS for 15 minutes and 6 drops of double distilled water. For double labeling, after the first Protein A gold incubation, grids were washed in 4 drops of PBS for a total of 15 minutes then transferred to a drop of 1% glutaraldehyde in PBS for 5 minutes, and washed in 4 drops of PBS/0.15M glycine. The second primary antibody was then applied, followed by PBS washing and treatment with different size Protein-A gold as above. Contrasting/embedding of the labeled grids was carried out on ice in 0.3% uranyl acetete in 2% methyl cellulose for 10 minutes. Grids were picked up with metal loops, leaving a thin coat of methyl cellulose. The grids were examined in a Tecnai G² Spirit BioTWIN transmission electron microscope and images were recorded with an AMT 2k CCD camera.
Preparation of photomicrographs
The digital images produced in Metamorph were assembled into composite images by using Adobe Photoshop 8.0 (Adobe Systems, San Jose, CA).
Results
The localization of angiogenesis regulatory proteins within the platelet is important for understanding how platelets contribute to new blood vessel formation. The 
platelets, we analyzed the distribution of angiogenic regulatory proteins in proplateletproducing mouse megakaryocytes. As observed in platelets, VEGF and endostatin were localized to separate α-granules in the proplatelet extensions (Figure 2a-c) . A similar segregated staining pattern was also observed for thrombospondin-1 and basic FGF (Figure 2d-f) as well as fibrinogen and vWf (Figure 2g-i) . Most vWf co-localized with the endostatin-containing α-granules (Figure 2j-l) . We confirmed the presence of distinct populations of α-granules in human platelets at the ultra-structural level using immunoelectron microscopy ( Figure 3 (Figure 3g ). Anti-P-selectin antibodies specifically labeled almost all α-granules and the plasma membrane of resting platelets (Figure 3g ). Quantitative analysis of gold labeling in serial sections revealed that antibodies to VEGF, endostatin, vWF and fibrinogen each stain approximately 50% of the granule population (Figure 3h ). In contrast, anti-P-selectin antibodies label the membrane of all α-granules as well as the surface of the resting platelet. Less than 10% of granules contained gold labeling for both endostatin and VEGF or vWF and fibrinogen together (Figure 3h ).
The packaging of VEGF and endostatin into separate α-granules suggested that distinct granule populations may undergo selective release. We tested this hypothesis by stimulating platelets with either PAR4-activating peptide or PAR1-activating peptide.
Selective granule release was assessed by immunofluorescence microscopy ( Figure 4 ).
Phalloidin staining demonstrated that exposure of platelets to either ligand resulted in aggregation and extension of lamellipodia and filopodia, leading to activation ( Figure   4b,d,f,h ). Immunofluorescence microscopy revealed that PAR4 treatment resulted in loss of the endostatin labeling, suggesting that most of the endostatin-containing granules were released from the platelets ligated with PAR4-activating peptide (Figure 4c ).
However, numerous VEGF-containing granules were retained in the cytoplasm of PAR4-treated platelets (Figure 4a ). In contrast, immunofluorescence microscopy revealed that ligation of PAR1 resulted in the release of VEGF-containing (green) granules, suggesting that release of VEGF-containing granules was elicited by the PAR1 agonist (Figure 4e ).
However, a large number of endostatin-containing granules were still retained in the cytoplasm of PAR1-treated platelets. (Figure 4g ). To confirm the phenomenon of differential granule release, we analyzed the agonist-mediated release of α-granules at higher resolution using immunoelectron microscopy. Stimulation of platelets with PAR4 agonist resulted in the release of almost all endostatin-containing granules; the majority (84%) of granules remaining in the activated platelets were positive for VEGF ( Figure   4i ). Treatment of platelets with PAR1 agonist induced the release of the majority of VEGF-containing granules; the majority (88%) of granules remaining in the PAR1-activated platelets were positive for endostatin (Figure 4j ).
DISCUSSION
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Angiogenesis is a critical element of many physiological processes such as wound healing, as well as pathological processes such as tumor growth. In both situations, new blood vessel development is driven locally, by the release of pro-angiogenic factors such as VEGF, bFGF, and PDGF. However, angiogenesis can also be inhibited by local release of antiangiogenic factors such as endostatin and thrombospondin. The proximity to and interaction with the endothelium allow platelets to strongly influence tumor development and wound healing. Platelets have been presumed to contribute to these angiogenesis-dependent processes by providing many pro-and antiangiogenic proteins, but their regulatory role is incompletely understood. In this study, we have shown that platelets contain distinct populations of α-granules that can undergo differential release in vitro. This study suggests that at least two populations of α-granules containing endogenous angiogenic regulatory proteins are present in platelets and raises the possibility that platelets contain multiple types of α-granules. Platelets contain a large number of angiogenic regulatory proteins, whose localization will need to be thoroughly established to understand the complexity of α-granule organization within resting platelets. Yet, it can be inferred that this subcellular organization has a physiological purpose in facilitating the differential release of these proteins in response to tissue stimuli. Our findings of differential granule release also support and provide a mechanistic explanation for earlier studies examining the secretion reaction of platelets.
Two independent groups have documented the differential release of α-granule proteins from platelets 25, 26 . In addition, morphometric evaluation of the platelet release reaction during thrombogenesis has demonstrated that platelets do not release all of their granules when they are incorporated into a thrombus 27 . The above results also raise the question , it appears that α-granules develop from budding vesicles in the Golgi complex within megakaryocytes, where they transform into multivesicular bodies, which also fuse with endocytic vesicles. Coated pits and vesicles have been observed in platelets and function to take up proteins, such as fibrinogen, by receptor mediated endocytosis.
These endocytic vesicles fuse with the multivesicular bodies. Multivesicular bodies, which are prevalent in early megakaryocytes, are believed to be a common precursor of both α-and dense granules. However, the mechanisms by which α-and dense granules develop into distinct entities are unknown. It is tempting to speculate that a similar process may be employed to segregate proteins into distinct subsets of α-granules, and that genetic defects which affect the α-granule segregation or differential release may d, e, f, Double immunofluorescence microscopy of resting platelets using antibodies against bFGF (d) and TSP-1 (e) and an overlay (f). g, h, i, Double immunofluorescence microscopy of resting platelets using antibodies against fibrinogen (g) and von
Willebrand factor (h) and an overlay (i). j, k, l, Double immunofluorescence microscopy of resting platelets using antibodies against von Willebrand factor (j) and endostatin (k) and an overlay (l). m, n, o, Double immunofluorescence microscopy of resting platelets using antibodies against VEGF (m) and fibrinogen (n) and an overlay (o). 
